Daunoblastina

Daunoblastina Dosage/Direction for Use

daunorubicin

Manufacturer:

Pfizer

Distributor:

Zuellig Pharma

Marketer:

DKSH
Full Prescribing Info
Dosage/Direction for Use
The single dose can vary from 0.5 to 3 mg/kg. The doses of 0.5-1 mg/kg can be repeated at intervals of 1 or more days; the doses of 2 mg/kg should be given at intervals of 4 or more days; the doses of 2.5-3 mg/kg, although rarely used, should be given only at intervals of 7-14 days. The number of injections required varies widely from patient to patient and should be prescribed for each individual case, depending on individual response and tolerability, taking into account blood chemistry and bone marrow conditions and any association with other antiblastic agents. In both adults and children it is recommended not to exceed the total dose of 20 mg/kg (see Precautions).
Hepatic impairment: The dosage of Daunorubicin should be reduced in patients who present impairment of liver function so as to avoid an increase in global toxicity.
It is recommended a dosage reduction in patients with the following chemical parameters in the blood: Daunorubicin should not be administered to patients with severe hepatic impairment (Child-Pugh Grade C [total score 10-15] - see Contraindications).
For patients with mild and moderate hepatic impairment (Child-Pugh Grade A [total score 5-6] and B [total score 7-9]), dose reductions are recommended based on the following serum bilirubin values: Bilirubin 1.2 to 3 mg/dL: one-half of recommended starting dose.
Bilirubin >3 mg/dL: one-fourth of recommended starting dose.
Renal impairment: For patients with moderate renal impairment, glomerular filtration rate (GFR) between 10-20 mL/min or serum creatinine approximately between 3.4-7.9 mg/dL, the daunorubicin dose should be reduced by one-half (see Contraindications).
Administration method: Daunorubicin is not active if taken orally and should not be administered by intramuscular or intrathecal route. Administration is to be effected only by intravenous injection; it is advisable to effect the injection into the tubing of an intravenous infusion of normal saline solution already in situ, after ascertaining that the needle is perfectly in the vein. This technique reduces the danger of the drug leaking out and ensures that the vein is well washed through after administration of the drug.
Daunorubicin must not be mixed with heparin since these drugs show chemical incompatibility and, in certain proportions, form a precipitate.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in